10x Genomics stock crashed Thursday after the medtech reported preliminary third-quarter sales that widely missed Street expectations.

--10 x Genomics, Inc., a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. With these ...

10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. Find out why TXG is poised for sustained growth.

Over the past 12-18 months, 10x Genomics has cemented itself as the leader of not only single-cell analysis, with its original Chromium platform, but also in spatial analysis.

Scaling only works when your cash flow, financial systems and tax strategy grow alongside your revenue. Here’s how to grow your business effectively, without running out of cash.

Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega-scale single cell analysis with improved efficiency and ease of use.

The recent acquisition by Vanguard has not only increased its share count in 10x Genomics Inc but also reinforced its strategy of investing in high-growth sectors.

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to ...

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to ...